

ACORDA THERAPEUTICS INC

Reported by
BLIGHT ANDREW

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 11/08/06 for the Period Ending 11/06/06

Address	420 SAW MILL RIVER ROAD ARDSLEY, NY 10502
Telephone	914-347-4300
CIK	0001008848
Symbol	ACOR
SIC Code	2836 - Biological Products, Except Diagnostic Substances
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549**

OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2008
Estimated average burden hours per response... 0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the
Investment Company Act of 1940

1. Name and Address of Reporting Person * Blight Andrew (Last) (First) (Middle) 15 SKYLINE DRIVE (Street) HAWTHORNE, NY 10532 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol ACORDA THERAPEUTICS INC [ACOR]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> X Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Scientific Officer
3. Date of Earliest Transaction (MM/DD/YYYY) <p align="center">11/6/2006</p>		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
4. If Amendment, Date Original Filed (MM/DD/YYYY) 		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Restricted stock	11/6/2006 (1)		S		200	D	\$16.22	103592	D	
Restricted stock	11/6/2006 (1)		S		600	D	\$16.15	102992	D	
Restricted stock	11/6/2006 (1)		S		700	D	\$16.14	102292	D	
Restricted stock	11/6/2006 (1)		S		400	D	\$16.13	101892	D	
Restricted stock	11/6/2006 (1)		S		200	D	\$16.12	101692	D	
Restricted stock	11/6/2006 (1)		S		800	D	\$16.11	100892	D	
Restricted stock	11/6/2006 (1)		S		300	D	\$16.10	100592	D	
Restricted stock	11/6/2006 (1)		S		1600	D	\$16.09	98992	D	
Restricted stock	11/6/2006 (1)		S		1400	D	\$16.08	97592	D	
Restricted stock	11/6/2006 (1)		S		2022	D	\$16.07	95570	D	
Restricted stock	11/6/2006 (1)		S		1900	D	\$16.06	93670	D	
Restricted stock	11/6/2006 (1)		S		3850	D	\$16.05	89820	D	
Restricted stock	11/6/2006 (1)		S		1200	D	\$16.04	88620	D	
Restricted stock	11/6/2006 (1)		S		4417	D	\$16.03	84203	D	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Restricted stock	11/6/2006 (1)		S		2000	D	\$16.02	82203	D	
Restricted stock	11/6/2006 (1)		S		800	D	\$16.01	81403	D	
Restricted stock	11/6/2006 (1)		S		1911	D	\$16.00	79492	D	
Restricted stock	11/6/2006 (1)		S		300	D	\$15.99	79192	D	
Restricted stock	11/6/2006 (1)		S		400	D	\$15.98	78792	D	

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

(1) Sale pursuant to a 10b5-1 plan

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Blight Andrew 15 SKYLINE DRIVE HAWTHORNE, NY 10532			Chief Scientific Officer	

Signatures

/s/ Andrew Blight

11/8/2006

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.